Hepion Secures $3.06M in Deeply Discounted Private Placement with Warrants
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals raised $3.06 million in a private placement priced at $0.05 per share — a deep discount to its $0.0013 stock — with warrants for an equal number of shares at $0.06. The deal is massively dilutive but provides essential cash for the going-concern company.
Key Events · Financing and Capital Events · CTRVP
-
Private Placement Priced at Deep Discount
The company sold 61.1 million shares at $0.05 per share — a price 38x higher than the current $0.0013 market price, but the offering is still deeply dilutive given the company's $2.1M market cap. Gross proceeds total $3.06 million.
-
Warrants Add Further Dilution Overhang
Warrants to purchase an additional 61.1 million shares at $0.06 per share were issued, exercisable for five years. If fully exercised, total shares outstanding would increase by 122.2 million, massively diluting existing holders.
-
Survival Capital for Going-Concern Company
Proceeds will be used for working capital. The company previously disclosed substantial doubt about its ability to continue as a going concern; this financing extends its cash runway but at a severe cost to shareholders.
-
Offering Closed August 3, 2026
The transaction closed on August 3, 2026, with shares and warrants issued to accredited investors in a private placement exempt from registration.
Analysis · CTRVP · Life Sciences
Facing a going-concern warning, micro-cap biotech Hepion Pharmaceuticals sold 61.1 million shares at $0.05 — a massive discount to the already depressed $0.0013 stock price — plus warrants for another 61.1 million shares at $0.06. The $3.06 million in proceeds is critical survival capital, but the structure is highly dilutive: the share issuance alone is roughly 30x the current market cap, and the warrants add further overhang. This is classic distressed financing — the company is paying a steep price in dilution to extend its runway.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.